ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0377 • ACR Convergence 2024

    Improving Self-Management Support in Patients with Juvenile Idiopathic Arthritis

    Julia Harris1, Leslie Favier2, Emily Fox3, Michael Holland3, Cara Hoffart4, Maria Ibarra3, Jordan Jones4, Susan Parish2, Kara Remick-Erickson2 and Ashley Cooper4, 1Children's Mercy Kansas City, Overland Park, KS, 2Children's Mercy Kansas City, Kansas City, 3Children's Mercy Hospital, Kansas City, MO, 4Children's Mercy Kansas City, Kansas City, MO

    Background/Purpose: Self-management support (SMS) is one of the key elements of the Chronic Care Model as it is an important aspect of the care for…
  • Abstract Number: 0741 • ACR Convergence 2024

    Serum Markers of Disease Activity in Polymyalgia Rheumatica

    Patricia Harkins1, Sharon Cowley2, seoidin McKittrick3, Robert Harrington4, David Kane5 and Richard Conway6, 1Trinity College Dublin, Dublin 8, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, 3University of Limerick, Limerick, Ireland, 4St. James's Hospital, Dublin, Dublin, Ireland, 5Tallaght University Hospital & Trinity College Dublin, D24, Ireland, 6Trinity College Dublin, Dublin, Ireland

    Background/Purpose: A significant unmet need in Polymyalgia Rheumatica (PMR) is the lack of a disease specific serum biomarker for diagnosis, and monitoring of disease activity.…
  • Abstract Number: 2455 • ACR Convergence 2024

    Improvement Across Multi-organ Domains and Patient Reported Outcomes in Refractory Juvenile-Onset Systemic Sclerosis (jSSc) up to 4 Years After Autologous Stem Cell Transplantation (ASCT)

    Jonathan Li1, Paulina Horvei2, Franziksa Rosser3, Kirsten Rose-Felker4, Vibha Sood5, Adam Olson6, Vickie Vandergrift7, Nicole Hogue2, Lauren Farver8, Devin Mcguire9, Haley Havrilla7, Jessie Alexander10, Shawna McIntyre2, Paul Szabolcs2 and Kathryn Torok11, 1Division of Rheumatology, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 2Division of Blood and Marrow Transplantation and Cellular Therapies, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 3Division of Pulmonology Medicine, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 4Division of Cardiology, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 5Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 6Department of Radiation Oncology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 7Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 8Department of Physical Therapy, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 9Pediatric Behavioral Health, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, 10Pediatric Bone Marrow Transplant and Cellular Therapies, Stanford Children's Hospital, Palo Alto, CA, USA, Pittsburgh, 11Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is a systemic autoimmune disease characterized by vasculopathy and multiorgan fibrosis leading to significant morbidity and early mortality.  Autologous stem…
  • Abstract Number: 2638 • ACR Convergence 2024

    Defining Sonographic Enthesitis in Psoriatic Arthritis: Developing a Data- and Expert-driven Diagnostic Criteria for Inflammatory Enthesitis at the Single Enthesis Level

    Andre Lucas Ribeiro1, Sibel Aydin2, Gurjit Kaeley3, Fahmeen Afgani4, Catherine Bakewell5, Marcos Rosemffet6, Minna Kohler7, Amir Haddad8, Maria S. Stoenoiu9, Ari Polachek10, josefina marin11, Arnon Katz12 and Lihi Eder13, 1Women's College Hospital & University of Toronto, Porto Alegre, Rio Grande do Sul, Brazil, 2University of Ottawa - Ottawa, Ottawa, ON, Canada, 3UF COM-J, Ponte Vedra Beach, FL, 4Women's College Hospital, Toronto, Canada, 5Intermountain Healthcare, Salt Lake City, UT, 6Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, 7Massachusetts General Hospital, Boston, MA, 8Carmel Medical Centre, Haifa, Israel, 9Cliniques Universitaires Saint-Luc, Brussels, Belgium, 10Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel, 11Hospital Italiano de Buenos Aires, buenos aires, Argentina, 12GRAPPA - Patient Research Partner, Haifa, Israel, 13University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada

    Background/Purpose: Clinical enthesitis occurs in 30-40% of psoriatic arthritis (PsA) patients, but its clinical diagnosis is challenging due to similarities to non-specific entheseal pain. Despite…
  • Abstract Number: 0384 • ACR Convergence 2024

    Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study

    Corey J. Bishop1, Edwin Lam2, Sophia G. Liva3, Jocelyn H. Leu2, Amy S. Paller4, Lucia Z. Diaz5, Laura Wine Lee6, Cory Rubin7, Ruy Carrasco8, Lisa Imundo9, Azadeh Majlessi10, Katherine Berezny1, Kathleen G. Lomax1, Valerie Smith1, Renping Zhang1 and hermine brunner11, 1Janssen Research & Development, Spring House, PA, 2Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, 3Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, 4Northwestern University, Feinberg School of Medicine, Chicago, IL, 5Dell Children’s Medical Center; Dell Medical School at the University of Texas at Austin, Austin, TX, 6Medical University of South Carolina, Charleston, SC, 7Michigan Dermatology Institute, Waterford, MI, 8Pediatric Rheumatology Consultants of Austin, Austin, TX, 9Columbia University Medical Center, New York, NY, 10Newport Huntington Medical Group, Huntington Beach, CA, 11Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH

    Background/Purpose: Ustekinumab (UST), an interleukin‑12/23p40 antagonist, is currently approved for juvenile psoriatic arthritis (jPsA) solely in the United States (US). Although a phase 3 study…
  • Abstract Number: 0744 • ACR Convergence 2024

    Cerebrovascular Accidents (CVA) in Giant Cell Arteritis: Identification of Predictive Factors from the ARTESER Registry

    Adrián Martín-Gutiérrez1, Juan Molina-Collada2, Marta Domínguez-Álvaro3, Rafael Benito Melero-Gonzalez4, Elisa Fernández-Fernández:5, Maite Silva-Diaz6, Jesús Alejandro Valero7, Ismael Gonzalez8, Julio Sánchez-Martín9, Javier Narvaez-García10, Itziar Calvo11, Vicente Aldasoro12, lydia Abasolo Alcazar13, ALBERTO MARIANO RUIZ ROMAN14, Javier Loricera15, Santos Castañeda16, Clara Molina Almela17, María Alcalde Villar:18, Antonio Juan-Mas19 and Ricardo Blanco-Alonso20, 1Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3Sociedad Española de Reumatología, Madrid, Spain, 4CHU Ourense, O Carballino, Spain, 5La Paz University Hospital, Alcalá de Henares, Madrid, Spain, 6Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, 7Hospital Universitario Donosti. Donostia, Spain, Donosti, Spain, 8Complejo Asistencial Universitario de Leon, León, Spain, 9Hospital Universitario 12 de Octubre, Madrid, Spain, 10Hospital Universitario de Bellvitge, Barcelona, Spain, 11Hospital Universitario de Basurto, Bilbao, Spain, 12Hospital Universitario de Navarra, Pamplona, Spain, 13IdISSC. HCSC, Madrid, Spain, 14Hospital Universitario Juan Ramón Jiménez, Huelva, Spain, 15Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 16Hospital Universitario de la Princesa, Madrid, Spain, 17Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, 18Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, 19Rheumatology Department, Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Cantabria, Spain, 20Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis in the elderly and involves the large and medium-sized vessels. Cerebrovascular accidents…
  • Abstract Number: 0716 • ACR Convergence 2024

    Outcomes of COVID-19 in Patients with ANCA-Associated Vasculitis (AAV)

    Husam El Sharu1, Teeba Mubaydeen2 and Maria Romero Noboa3, 1East Carolina University, Greenville, NC, 2King Hussein Cancer Center, Amman, Jordan, 3University of Alabama at Birmingham, Chicago, IL

    Background/Purpose: Patients with AAVs are typically on immunosuppression medications that might increase their risk of severe infections. COVID-19 has been associated with severe pulmonary manifestations…
  • Abstract Number: 2654 • ACR Convergence 2024

    Adapting and Testing a Cognitive Rehabilitation Intervention Tailored for People with Systemic Sclerosis: Acceptability, Feasibility, & Impact on Health-related Outcomes

    Yen Chen1, Mary Alore2, Dinesh Khanna1 and Susan Murphy3, 1University of Michigan, Ann Arbor, MI, 2Self-employed, TROY, MI, 3University of Michigan, Plymouth, MI

    Background/Purpose: Cognitive dysfunction affects up to 87% of individuals with systemic sclerosis (SSc), often significantly impairing their work and daily activities and exacerbating other symptoms…
  • Abstract Number: 0768 • ACR Convergence 2024

    Addressing Gaps in Polymyalgia Rheumatica: A Systematic Literature Review

    Shelley Fritz1, Angela Degrassi2, Kelly Gavigan2, Ruohan Hong3, Santiago Munoz Perez2, Esteban Rivera4, Erik Stone5, Laura Stradford6, Ambika Vartak2, Anne Sydor2 and Shilpa Venkatachalam3, 1Global Healthy Living Foundation, Kalaheo, HI, 2Global Healthy Living Foundation, Upper Nyack, NY, 3Global Healthy Living Foundation, New York, NY, 4Global Healthy Living Foundation, Long Island City, NY, 5Global Healthy Living Foundation, Upper Nyack, 6Global Healthy Living Foundation, Nyack, NY

    Background/Purpose: This systematic literature review on polymyalgia rheumatica (PMR) and PMR with giant cell arteritis (GCA) evaluates existing literature on disease burden, management, and treatment…
  • Abstract Number: 0365 • ACR Convergence 2024

    Patients’ Behaviors and Beliefs Around Dietary Changes Among a Cohort of Patients with Rheumatic Disease

    Aaron Stubbs, Deeba Minhas, Anne Arewasikporn and Andrew Schrepf, University of Michigan, Ann Arbor, MI

    Background/Purpose: Dietary interventions may help manage inflammation and are considered for adjunctive treatment of rheumatic diseases.  Our study aimed to explore patients' behaviors and beliefs…
  • Abstract Number: 0380 • ACR Convergence 2024

    Joint Acoustic Emissions as a Digital Biomarker for Knee Inflammation in Juvenile Idiopathic Arthritis: A Pilot Study Using Musculoskeletal Ultrasound as Ground Truth

    Quentin Goossens1, Christopher Nichols1, Diana Sofia Villacis-Nunez2, Lori Ponder3, Omer Inan4 and Sampath Prahalad5, 1Georgia Institute of Technology, Atlanta, GA, 2Emory University School of Medicine, Atlanta, GA, 3Children's Healthcare of Atlanta, Atlanta, GA, 4Georgia Institute of Technology, Marietta, GA, 5Emory + Children's Pediatric Institute, Atlanta, GA

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic childhood arthropathy affecting 1 in 1000 children under 16, classified into seven categories by ILAR. Commonly, JIA…
  • Abstract Number: 0378 • ACR Convergence 2024

    Disparate Disease Activity Outcomes Associated with Demographic Variables in Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry

    Julia Harris1, Catherine Bingham2, Sheetal Vora3, Cagri Yildirim-Toruner4, Kerry Ferraro5, Erik Friedrichsen6, Michelle Batthish7, Jon Burnham8, Danielle Fair9, Suhas Ganguli10, Mileka Gilbert11, Beth Gottlieb12, Tzielan Lee13, Daniel Lovell14, Melissa Mannion15, Edward Oberle16, Nancy Pan17, Linda Ray18, Michael Shishov19, Mary Toth20 and Esi Morgan21, 1Children's Mercy Kansas City, Overland Park, KS, 2Penn State Children’s Hospital, Hershey, 3Atrium Health Levine Children's Hospital, Charlotte, NC, 4Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, 5JIA parent and CHOP volunteer, Lower Gwynedd, PA, 6Seattle Children's Hospital, Seattle, 7McMaster Children's Hospital, Hamilton, ON, Canada, 8Children's Hospital of Philadelphia, Philadelphia, PA, 9Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, 10Hackensack University Medical Center, Hackensack, 11Medical University of South Carolina, Charleston, SC, 12Cohen Children's Medical Center, Lake Success, NY, 13Stanford University School of Medicine, Palo Alto, CA, 14Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 15University of Alabama at Birmingham, Birmingham, AL, 16Nationwide Children's Hospital, Columbus, OH, 17Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 18University of Mississippi Medical Center, Jackson, MS, 19Phoenix Children's Hospital, Phoenix, AZ, 20Nemours Foundation, Orlando, FL, 21Seattle Children's Hospital, Seattle, WA

    Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a North American learning health network focused on improving outcomes in patients with juvenile…
  • Abstract Number: 0375 • ACR Convergence 2024

    Patient Outcomes During the Implementation of a Patient Decision-Aid for a Diverse Population of Systemic Lupus Erythematosus: A Study in 15 U.S. Rheumatology Clinics

    Jasvinder Singh1, Larry Hearld2, Walter Chatham3, Sonali Narain4, Narender Annapureddy5, Diane Kamen6, Kimberly Trotter7, vikas Majithia8, Zineb Aouhab9, Swamy Venuturupalli10, Daniel Wallace11, rosalind Ramsey-Goldman12, Alfred Kim13, Maureen McMahon14, S. Sam Lim15, Kalpana Bhairavarasu16, Alexa Meara17, Kenneth Kalunian18 and Cathy Lee Ching19, 1Baylor College of Medicine, Birmingham, AL, 2University of Alabama at Birmingham (UAB), Birmingham, AL, 3University of Nevada, Las Vegas, Las Vegas, NV, 4Northwell Health, Great Neck, NY, 5Vanderbilt University Medical Center, Nashville, TN, 6Medical University of South Carolina, Charleston, SC, 7University of Chicago, Chicago, IL, 8University of Missisippi Medical Center (UMC), Jackson, MS, 9Loyola University Medical Center, Oak Brook, IL, 10Attune Health, Beverly Hills, CA, 11Cedars Sinai Medical Center, Studio City, CA, 12Northwestern University, Chicago, IL, 13Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, 14UCLA David Geffen School of Medicine, Los Angeles, CA, 15Emory University, Atlanta, GA, 16Baylor College of Medicine, Sugar Land, TX, 17The Ohio State University Wexner Medical Center, COLUMBUS, OH, 18University of California San Diego, La Jolla, CA, 19UMMC, Jackson, MS

    Background/Purpose: To implement a self-administered patient decision-aid (PtDA) for lupus in outpatient clinics, assess its reach/penetration within each clinic, and examine patient outcomesMethods: An effective…
  • Abstract Number: 0381 • ACR Convergence 2024

    Two- and 3-Year Outcomes of the Childhood Arthritis and Rheumatology Research Alliance FROST Study of New-onset Systemic JIA Treatment

    Timothy Hahn1, George Tomlinson2, Yukiko Kimura3, Vincent Del Gaizo4, Carlos Valdes5 and Timothy Beukelman6, and for the CARRA FROST Investigators, 1Penn State Childrens Hospital, Hershey, PA, 2University of Toronto, Toronto, ON, Canada, 3Hackensack Meridian School of Medicine, New York, NY, 4Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, 5Genentech, Davie, FL, 6University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The FiRst Line Options for sJIA Treatment (FROST) trial was a prospective observational study designed to compare the effectiveness of 4 Childhood Arthritis and…
  • Abstract Number: 0366 • ACR Convergence 2024

    Factors Associated with Participation in Rheumatology Clinical Trials: A UK-based Study

    Koushan Kouranloo1 and Chris Wincup2, 1Internal Medicine Resident., London, United Kingdom, 2King's College Hospital, London, United Kingdom

    Background/Purpose: Clinicians are encouraged to consider patient preferences for offering face-to-face vs virtual consultations. This adaptability is particularly important to rheumatologists caring for patients with…
  • « Previous Page
  • 1
  • …
  • 229
  • 230
  • 231
  • 232
  • 233
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology